Partners
Join us, become a member of our integrated partner network
Science requires teamwork. Data quality requires diligence. AsedaSciences believes the 3RnD platform will be stronger using a community approach embracing these core elements. If you feel you have a validated biological screening method, analytical technology or software application that is synergistic with the 3RnD platform, we would like to discuss partnering with you, so please contact us.
Our partners
Validated screening methods, analytical technologies and software, integrated in the 3RnD platform. Click a logo to read about the partnership.
NAMs Central™
One location. Multiple methods. Integrated results. Better decisions.
NAMs Central™ brings together best-in-class New Approach Methods, predictive models, and experienced screening providers, from analytical and cell-based assays to whole-organism and advanced human-on-chip™ models.
Visit NAMs Central to place orders, or Our Biology in the Knowledge Center to learn more about each method.
Biomimetics / Lipophilicity
Compound Solubility
Acute Cellular Stress
Developmental Neurotoxicity
Cardiotoxicity
G-Protein Coupled Receptors
Kinome Screen
Ames Test, Mutagenicity
Micronucleus Test
Aquatic Toxicity
Dermal Toxicity
Endocrine Disruption
Neurotoxicity
Hepatotoxicity / DDI
Human-on-a-Chip
Biomimetic HPLC
Chromatographic profiling with Dr. Klara Valko
Chromatographic profiling of chemical analogs by measuring their non-specific binding to proteins and phospholipids, can be used to model in vivo distribution and select compounds with the desired in vivo behavior, providing an early estimate of the therapeutic dose and drug efficiency. A balanced potency and chromatographically determined membrane and protein binding ensure the selection of compounds with the highest probability to show the desired in vivo distribution behavior for efficacy and reduced toxicity. This in turn helps with the earlier selection of scaffolds or analogs in an SAR series with reduced risk to human safety.
This approach was pioneered by Dr. Klara Valko and is now routinely used across the industry. AsedaSciences has partnered with Dr. Valko to provide these services out of the UK and USA.
Cardiotoxicity
Clyde Biosciences
Clyde Biosciences provides human-relevant cardiovascular safety testing using iPSC-derived cardiomyocytes and its proprietary CellOPTIQ® platform, which simultaneously measures voltage, calcium, and contractility in the same cells. This high-content, validated CiPA assay provides clinically predictive insights into proarrhythmic and negative inotropic risk, supporting earlier drug-development decisions and IND-enabling studies while advancing human-relevant, non-animal safety assessment.
Zebrafish Embryo Screen
Tanguay Lab
The Tanguay Lab is an internationally recognized leader in zebrafish embryo and whole-organism screening for developmental neurotoxicity, acute toxicity, and aquatic toxicity risk. Through NAMs Central™, customers can order the Tanguay Lab’s gold-standard, automated, high-throughput ZBEscreen to generate standardized organ and behavioral profiles for their own compounds. These profiles can then be compared with thousands of reference compounds across pharmaceutical, cosmetic, industrial, and agricultural chemical classes. This validated early development screening approach complements cell-based toxicity data and can reveal behavioral effects not detectable in cell culture, providing deeper biological insight for earlier, more informed compound prioritization decisions.
Ames MPF Test, Mutagenicity
Xenometrix
Xenometrix provides high-throughput mutagenicity screening using the miniaturized Ames MPF (microplate fluctuation) assay, a liquid microplate adaptation of the Ames test designed for efficient early genotoxicity assessment. This next-generation platform delivers results closely correlated with traditional agar plate assays while significantly reducing compound consumption, reagents, plastic waste, and hands-on time. Its microplate format enables automation and supports both GLP and non-GLP studies with rapid turnaround. Integration with the 3RnD platform digitizes assay outputs, enabling automated data capture, analysis, and scalable compound screening. This combination of miniaturization, automation, and digital visualization provides a cost-efficient, high-throughput solution for early mutagenicity testing while maintaining regulatory relevance.
Micronucleus Genotoxicity
GenEvolutioN
GenEvolutioN’s Micronucleus Screen is a next-generation genotoxicity platform that combines human primary lymphocytes with telomere and centromere Fluorescence In Situ Hybridization (FISH) staining. By classifying micronuclei as aneugenic or clastogenic, the assay delivers mechanistic resolution beyond that provided by standard micronucleus tests. Conducted in primary human cells, it maximizes translational relevance to human biology. Automated high-content imaging combined with AI-driven deep learning analysis enables scalable, reproducible screening while minimizing operator bias. Fully aligned with OECD TG 487 and ISO 21427-1, and supported by more than 50 years of scientific expertise and GLP accreditation, the platform provides a human-relevant NAM for modern genotoxicity risk assessment.
Kinome Profiling
AssayQuant
AssayQuant provides KinSight™ kinome profiling services using continuous PhosphoSens® technology to measure true kinase catalytic activity in real time. Unlike binding-based or endpoint assays, KinSight captures full reaction progress curves in each well, calculating reaction rates from multiple time points to generate highly reliable activity measurements. This approach reveals kinetic features such as time-dependent or irreversible inhibition while providing built-in assay quality control. The platform supports profiling across ~400 wild-type kinases, with options for mutant kinases or customized safety panels. By linking functional kinase activity changes to known Adverse Outcome Pathways (AOPs), KinSight enables earlier identification of off-target liabilities and supports tiered NAM strategies for safer chemical and drug development.
GPCR Profiling
EuroscreenFast™
EuroscreenFast provides high-throughput GPCR screening and profiling across 530+ targets and 1,000+ functional and radioligand binding assays, with safety, organ-specific, and custom panels available in agonist and antagonist modes. With more than 30 years of GPCR expertise, EuroscreenFast delivers highly reproducible data that, when combined with cell-based toxicity, organ, and kinome screens, provides a broader view of off-target activity and mechanisms of toxicity, supporting earlier, more informed compound selection and risk assessment.
Aquatic Toxicity Profiling
Biobide
Biobide provides industry-leading aquatic toxicity screening across zebrafish embryo, Daphnia, and algae models, including organ-specific zebrafish endpoints. Through its integration with 3RnD®, customers can order these NAM-based screens directly through NAMs Central™, with study data delivered into the platform for visualization and analysis. This multi-species approach provides complementary insights into acute, organ-specific, and environmental toxicity, helping scientists identify potential risks earlier and make more informed decisions earlier in chemical development.
Human-on-a-Chip™
Hesperos
Hesperos provides advanced human organ-on-chip platforms that replicate multi-organ physiology to generate highly predictive, human-relevant data on efficacy, toxicity, and pharmacokinetics. Integration of Hesperos systems into the 3RnD platform enables researchers to directly link complex, dynamic in vitro data with compound structures, biological pathways, and external datasets. This connection allows users to explore how compounds behave across interconnected organ systems, improving translational insight beyond traditional assays. By combining organ-level functional data with advanced visualization and analytics, the platform supports more informed decision-making, reduces reliance on animal models, and accelerates the development of safer, more effective chemicals and therapeutics.
Cell Lines for Profiling
Cytion
Cytion, a premier cell bank specializing in authenticated human and animal cell lines, provides high-quality, contamination-free biological models trusted by researchers worldwide. Renowned for rigorous quality control and genetic authentication, Cytion delivers reliable cell culture solutions rapidly for diverse research applications. By integrating its portfolio directly into the 3RnD platform, users can identify and select relevant cell models while simultaneously exploring associated experimental, mechanistic, and literature-derived data. By linking trusted cellular models with curated scientific datasets and advanced visualization tools, researchers can more quickly identify cell lines with the desired target expression profiles, saving time and enabling faster data generation rather than prolonged data searching.
Corpus Chemicum™
Redpine
Corpus Chemicum™, powered by Redpine’s licensed, AI-driven scientific data engine within the 3RnD® Knowledge Center, enables researchers to search scientific and clinical literature using natural-language prompts and retrieve relevant verbatim excerpts sourced from across full publications, not just abstracts or summaries. It connects in vitro, in vivo, and human evidence on compounds, biological effects, clinical trials, adverse events, toxicity, and disease, helping scientists rapidly find relevant data and biological insights, identify potential safety risks, and make informed decisions across pharmaceutical, cosmetic, agricultural, and industrial chemical development.
Excelra
GOSTAR® small molecule data inside 3RnD®
Excelra is a global small molecule data and analytics leader, providing knowledge-driven solutions that are at the cutting edge of life sciences innovation, spanning the entire drug discovery and development continuum. Known for its comprehensive data curation and analysis of small molecules, Excelra is a trusted partner in the global pharmaceutical and biotech community, helping to inform scientists on advancements in medicine and environmental safety.
AsedaSciences has a strategic collaboration with Excelra to integrate and market Excelra's GOSTAR® platform through AsedaSciences' 3RnD® platform. This integration sets a new benchmark for information consolidation, providing cost-effective content and information accessibility through a single, easy to use interface for scientists across academic drug discovery and small to medium size biotechnology companies.
Disease Atlas
Euretos
Euretos has developed their comprehensive Disease Atlas by integrating published literature, patents and over 100 multi-omics databases, creating a curated knowledge graph linking genes, proteins, pathways, diseases, and therapeutics. Through integration within the 3RnD platform, researchers can explore complex biological relationships and disease mechanisms alongside experimental and literature-derived data. This connection enables users to rapidly identify target and disease associations, uncover mechanistic insights, and evaluate potential efficacy or safety signals within a unified analytical environment. By combining structured biomedical knowledge with advanced visualization and data integration capabilities, the platform supports hypothesis generation, target validation, and more informed decision-making across discovery, translational research, and development workflows.
Chemspace
A multi-trillion compound library inside 3RnD
Chemspace has partnered with AsedaSciences to make its multi-trillion compound library accessible within the 3RnD platform through the integrated ChOSMOS™ and Chemporium applications. Researchers can search by structural similarity, assemble compound sets, and place orders within a single interface, without switching between tools.
Integration with 3RnD NAM Central connects sourced compounds directly to biological and cellular screening services, enabling teams to move from compound selection to assay data within one platform.
By combining large-scale compound sourcing with high-content biological insights, this unified workflow helps accelerate compound selection, experimental design, and data-driven decision-making across discovery, screening, and early preclinical research.
Cayman Chemical
Curated compound libraries, available through 3RnD
AsedaSciences has partnered with Cayman Chemical, a leading supplier and manufacturer of high-quality, high-purity biochemicals, to screen several comprehensive compound libraries. These compounds and the associated biological fingerprints are available for comparison within the 3RnD database.
Cayman is an industry leader in the creation of high-value compound libraries to simplify screening efforts. These libraries, which include antiviral, anti-inflammatory, and kinase screening libraries, are skillfully curated to maximize the number of biologically relevant targets. All compounds are expertly controlled for quality to ensure the best possible results. Cayman also offers thousands of well-characterized biochemicals, as well as custom synthesis, medicinal chemistry, and analytical chemistry services to support drug discovery efforts. The Cayman Compound library is conveniently available to purchase through the 3RnD platform.
eMolecules
Compound management for NAMs Central™
AsedaSciences has partnered with eMolecules to bring professional compound management services into the NAMs Central™ ecosystem within 3RnD®. The integrated offering helps ensure compounds entering analytical and biological testing are correctly identified, accurately prepared, properly stored, and rigorously quality controlled, so the right molecule, at the right concentration and verified purity, is the starting point for every screen.
Compound integrity is the critical first step toward reliable data. Degradation, contamination, impurities, or incorrect concentrations can alter biological responses, compromise study results, and lead to costly false conclusions. From digitizing compound libraries and stock solutions to storage, retrieval, preparation, QC, and logistics, eMolecules helps ensure the right molecule reaches the right test at the right concentration, providing a trusted foundation for downstream testing and decision-making.
CellPort
Full traceability for cell culture
CellPort will be integrated directly into 3RnD, providing full traceability of cell culture protocols, operators, and materials from early R&D through commercial deployment. By automating manual recording and quality assurance processes, this integration saves time, ensures operational consistency, and supports both non-GLP and GLP workflows. For companies using or developing cell-based New Approach Methods (NAMs) intended for IND submissions, CellPort’s comprehensive tracking of cell lineage, culture runs, and batch histories provides confidence in results, facilitates targeted troubleshooting, and prepares organizations for regulatory audits. Within 3RnD, NAM results are directly linked to detailed cell culture data, enabling transparent, reliable, and fully auditable workflows.
Simplicis
Ledger™, full traceability for chemicals
The Ledger™ platform by Simplicis will be integrated into 3RnD, providing full traceability for chemical sourcing, inventory, and usage throughout experimental workflows. By automating manual tracking and linking chemical metadata to assay results, this integration saves time, ensures operational consistency, and supports compliance with GLP and non-GLP requirements. For companies running cell-based New Approach Methods (NAMs), Ledger connects the third critical element, chemicals, to both the biological models and resulting data, enabling transparent mapping of compounds to experimental outcomes. This unified platform will allow researchers to analyze compound and cell interactions with full provenance, improving reproducibility, supporting regulatory audits, and streamlining data-driven decision-making across discovery and preclinical workflows.
